)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Citius Pharmaceuticals
Citius Pharmaceuticals (CTXR) investor relations material
Citius Pharmaceuticals H.C. Wainwright 28th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 28th Annual Global Investment Conference summary15 Sep, 2026
Company background and structure
Founded in 2014, with significant direct investment from founders and a public listing achieved via SPAC acquisition.
Structure includes a parent (Citius Pharmaceuticals) and subsidiary (Citius Oncology), with shared management to minimize expenses.
Key assets include LYMPHIR (oncology), Mino-Lok (infected catheter treatment), and Halo-Lido (hemorrhoid drug).
LYMPHIR launch and commercialization
LYMPHIR approved for cutaneous T-cell lymphoma (CTCL), targeting a $400–$500 million market, with U.S. rights secured.
Early sales achieved with a small team; full sales force of 29 deployed recently, expected to impact results in late 2026 and early 2027.
$7.1 million in revenue generated in less than nine months, with 44 institutions and 135 health plans adopting the drug.
Gross margin stands at 77%, aided by lack of managed care rebates due to hospital drug status.
Inventory is robust, with a five-year shelf life, and payer access is comprehensive.
Clinical and market insights
LYMPHIR’s mechanism targets IL-2 receptors, depleting Tregs and showing a 36% objective response rate in trials.
Durable responses and manageable side effects reported; competition includes ADCETRIS and Poteligeo.
Market is concentrated geographically and among a small number of providers, facilitating targeted sales.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Citius Pharmaceuticals
- Strong early adoption of a new oncology drug and a valuation gap create investment potential.CTXR
Moody Capital Disruptive Growth & Life Science Conference - LYMPHIR launch drove $7.1M nine-month revenue and 77% margin, but net loss hit $49.4M.CTXRQ3 2026
- Offering up to 5.4M shares underlying warrants, with proceeds supporting working capital amid Nasdaq compliance risks.CTXRRegistration filing
- $5.6M LYMPHIR revenue, 80% margin, $19.7M contract fee, $41.5M new financing.CTXRQ2 2026
- Election of seven directors and auditor ratification are up for vote at the April 2026 meeting.CTXRProxy Filing
- Shareholders will elect directors, ratify the auditor, and review executive compensation and governance.CTXRProxy Filing
- LYMPHIR launch drove $3.94M revenue, 80% margin, narrowing net loss but cash needs remain.CTXRQ1 2026
- FDA approval, pipeline momentum, and a strategic spin-off drive growth and new revenue streams.CTXRSidoti Micro-Cap Virtual Conference
- FDA approval of LYMPHIR and Citius Oncology spin-off drive transition to commercial-stage growth.CTXRInvestor Update
Next Citius Pharmaceuticals earnings date
Q4 202623 Dec, 2026
Citius Pharmaceuticals
Next Citius Pharmaceuticals earnings date
Q4 202623 Dec, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing critical care products. The company's pipeline includes a range of therapeutic candidates targeting various medical needs. Key products include Mino-Lok, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections, and LYMPHIR, a targeted immunotherapy recently approved by the FDA for treating relapsed or refractory cutaneous T-cell lymphoma (CTCL). Another notable product is CITI-002 (Halo-Lido), a topical formulation aimed at providing relief for hemorrhoids. The company is based in Cranford, New Jersey, and its shares are traded on the Nasdaq.